714 related articles for article (PubMed ID: 25434924)
1. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
[TBL] [Abstract][Full Text] [Related]
2. Implementation of mechanism of action biology-driven early drug development for children with cancer.
Pearson AD; Herold R; Rousseau R; Copland C; Bradley-Garelik B; Binner D; Capdeville R; Caron H; Carleer J; Chesler L; Geoerger B; Kearns P; Marshall LV; Pfister SM; Schleiermacher G; Skolnik J; Spadoni C; Sterba J; van den Berg H; Uttenreuther-Fischer M; Witt O; Norga K; Vassal G;
Eur J Cancer; 2016 Jul; 62():124-31. PubMed ID: 27258969
[TBL] [Abstract][Full Text] [Related]
3. Targeted approaches to childhood cancer: progress in drug discovery and development.
Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
[TBL] [Abstract][Full Text] [Related]
4. New drugs for children and adolescents with cancer: the need for novel development pathways.
Vassal G; Zwaan CM; Ashley D; Le Deley MC; Hargrave D; Blanc P; Adamson PC
Lancet Oncol; 2013 Mar; 14(3):e117-24. PubMed ID: 23434337
[TBL] [Abstract][Full Text] [Related]
5. Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson ADJ; Zwaan CM; Kolb EA; Karres D; Guillot J; Kim SY; Marshall L; Tasian SK; Smith M; Cooper T; Adamson PC; Barry E; Benettaib B; Binlich F; Borgman A; Brivio E; Capdeville R; Delgado D; Faller D; Fogelstrand L; Fraenkel PG; Hasle H; Heenen D; Kaspers G; Kieran M; Klusmann JH; Lesa G; Ligas F; Mappa S; Mohamed H; Moore A; Morris J; Nottage K; Reinhardt D; Scobie N; Simko S; Winkler T; Norga K; Reaman G; Vassal G
Eur J Cancer; 2020 Sep; 136():116-129. PubMed ID: 32688206
[TBL] [Abstract][Full Text] [Related]
6. [Specificity of paediatric oncology pharmacology].
André N; Leblond P; Verschuur A
Bull Cancer; 2010 Feb; 97(2):191-8. PubMed ID: 19812009
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials in paediatric oncology. Recommendations for the development of new anticancer agents.
Vassal G; Méry-Mignard D; Caulin C
Therapie; 2003; 58(3):229-46. PubMed ID: 14655318
[TBL] [Abstract][Full Text] [Related]
8. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
9. Will children with cancer benefit from the new European Paediatric Medicines Regulation?
Vassal G
Eur J Cancer; 2009 Jun; 45(9):1535-46. PubMed ID: 19419857
[TBL] [Abstract][Full Text] [Related]
10. Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives.
Seifert G; Budach V; Keilholz U; Wust P; Eggert A; Ghadjar P
Radiat Oncol; 2016 Apr; 11():65. PubMed ID: 27138749
[TBL] [Abstract][Full Text] [Related]
11. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
12. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
Rose K
Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
14. Progress review of the European Paediatric Regulatory Framework after six years of implementation.
Mentzer D
Int J Pharm; 2014 Aug; 469(2):240-3. PubMed ID: 24613178
[TBL] [Abstract][Full Text] [Related]
15. ACCELERATE - Five years accelerating cancer drug development for children and adolescents.
Pearson ADJ; Weiner SL; Adamson PC; Karres D; Reaman G; Rousseau R; Blanc P; Norga K; Skolnik J; Kearns P; Scobie N; Barry E; Marshall LV; Knox L; Caron H; Wariabharaj D; Pappo A; DuBois SG; Gore L; Kieran M; Weigel B; Fox E; Nysom K; de Rojas T; Vassal G
Eur J Cancer; 2022 May; 166():145-164. PubMed ID: 35290915
[TBL] [Abstract][Full Text] [Related]
16. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ
Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773
[TBL] [Abstract][Full Text] [Related]
17. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
Rose K; Senn S
Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
[TBL] [Abstract][Full Text] [Related]
18. Changing incentives to ACCELERATE drug development for paediatric cancer.
de Rojas T; Kearns P; Blanc P; Skolnik J; Fox E; Knox L; Rousseau R; Doz F; Bird N; Pearson AJ; Vassal G
Cancer Med; 2023 Apr; 12(7):8825-8837. PubMed ID: 36645217
[TBL] [Abstract][Full Text] [Related]
19. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
20. The role of the 'innovative therapies for children with cancer' (ITCC) European consortium.
Zwaan CM; Kearns P; Caron H; Verschuur A; Riccardi R; Boos J; Doz F; Geoerger B; Morland B; Vassal G;
Cancer Treat Rev; 2010 Jun; 36(4):328-34. PubMed ID: 20231057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
